Skip to main content
Erschienen in: Abdominal Radiology 8/2019

27.04.2019 | Pelvis

Extracapsular extension on MRI indicates a more aggressive cell cycle progression genotype of prostate cancer

verfasst von: Andreas G. Wibmer, Nicola L. Robertson, Hedvig Hricak, Junting Zheng, Marinela Capanu, Steven Stone, Behfar Ehdaie, Michael K. Brawer, Hebert Alberto Vargas

Erschienen in: Abdominal Radiology | Ausgabe 8/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To explore associations between magnetic resonance imaging (MRI) features of prostate cancer and expression levels of cell cycle genes, as assessed by the Prolaris® test.

Materials and methods

Retrospective analysis of 118 PCa patients with genetic testing of biopsy specimen and prostate MRI from 08/2013 to 11/2015. Associations between the cell cycle risk (CCR) score and MRI features [i.e., PI-RADSv2 score, extracapsular extension (ECE), quantitative metrics] were analyzed with Fisher’s exact test, nonparametric tests, and Spearman’s correlation coefficient. In 41 patients (34.7%), test results were compared to unfavorable features on prostatectomy specimen (i.e., Gleason group ≥ 3, ECE, lymph node metastases).

Results

Fifty-four (45.8%), 60 (50.8%), and 4 (3.4%) patients had low-, intermediate-, and high-risk cancers according to American Urological Association scoring system. Patients with ECE on MRI had significantly higher mean CCR scores (reader 1: 3.9 vs. 3.2, p = 0.015; reader 2: 3.6 vs. 3.2, p = 0.045). PI-RADSv2 scores and quantitative MRI features were not associated with CCR scores. In the prostatectomy subset, ECE on MRI (p = < 0.001–0.001) and CCR scores (p = 0.049) were significantly associated with unfavorable histopathologic features.

Conclusion

The phenotypic trait of ECE on MRI indicates a more aggressive genotype of prostate cancer.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Kane CJ, Eggener SE, Shindel AW, Andriole GL (2017) Variability in Outcomes for Patients with Intermediate-risk Prostate Cancer (Gleason Score 7, International Society of Urological Pathology Gleason Group 2-3) and Implications for Risk Stratification: A Systematic Review. Eur Urol Focus. https://doi.org/10.1016/j.euf.2016.10.010 Kane CJ, Eggener SE, Shindel AW, Andriole GL (2017) Variability in Outcomes for Patients with Intermediate-risk Prostate Cancer (Gleason Score 7, International Society of Urological Pathology Gleason Group 2-3) and Implications for Risk Stratification: A Systematic Review. Eur Urol Focus. https://​doi.​org/​10.​1016/​j.​euf.​2016.​10.​010
2.
Zurück zum Zitat Cooperberg MR, Pasta DJ, Elkin EP et al (2005) The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 173:1938-1942CrossRefPubMedPubMedCentral Cooperberg MR, Pasta DJ, Elkin EP et al (2005) The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 173:1938-1942CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Touijer K, Scardino PT (2009) Nomograms for staging, prognosis, and predicting treatment outcomes. Cancer 115:3107-3111CrossRefPubMed Touijer K, Scardino PT (2009) Nomograms for staging, prognosis, and predicting treatment outcomes. Cancer 115:3107-3111CrossRefPubMed
5.
Zurück zum Zitat Moschini M, Spahn M, Mattei A, Cheville J, Karnes RJ (2016) Incorporation of tissue-based genomic biomarkers into localized prostate cancer clinics. BMC Med 14:67CrossRefPubMedPubMedCentral Moschini M, Spahn M, Mattei A, Cheville J, Karnes RJ (2016) Incorporation of tissue-based genomic biomarkers into localized prostate cancer clinics. BMC Med 14:67CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Taghipour M, Ziaei A, Alessandrino F et al (2018) Investigating the role of DCE-MRI, over T2 and DWI, in accurate PI-RADS v2 assessment of clinically significant peripheral zone prostate lesions as defined at radical prostatectomy. Abdom Radiol (NY). https://doi.org/10.1007/s00261-018-1807-6 Taghipour M, Ziaei A, Alessandrino F et al (2018) Investigating the role of DCE-MRI, over T2 and DWI, in accurate PI-RADS v2 assessment of clinically significant peripheral zone prostate lesions as defined at radical prostatectomy. Abdom Radiol (NY). https://​doi.​org/​10.​1007/​s00261-018-1807-6
9.
Zurück zum Zitat Tamada T, Dani H, Taneja SS, Rosenkrantz AB (2017) The role of whole-lesion apparent diffusion coefficient analysis for predicting outcomes of prostate cancer patients on active surveillance. Abdom Radiol (NY) 42:2340-2345CrossRef Tamada T, Dani H, Taneja SS, Rosenkrantz AB (2017) The role of whole-lesion apparent diffusion coefficient analysis for predicting outcomes of prostate cancer patients on active surveillance. Abdom Radiol (NY) 42:2340-2345CrossRef
11.
Zurück zum Zitat Holtz JN, Silverman RK, Tay KJ et al (2018) New prostate cancer prognostic grade group (PGG): Can multiparametric MRI (mpMRI) accurately separate patients with low-, intermediate-, and high-grade cancer? Abdom Radiol (NY) 43:702-712CrossRef Holtz JN, Silverman RK, Tay KJ et al (2018) New prostate cancer prognostic grade group (PGG): Can multiparametric MRI (mpMRI) accurately separate patients with low-, intermediate-, and high-grade cancer? Abdom Radiol (NY) 43:702-712CrossRef
12.
Zurück zum Zitat Glazer DI, Hassanzadeh E, Fedorov A et al (2017) Diffusion-weighted endorectal MR imaging at 3T for prostate cancer: correlation with tumor cell density and percentage Gleason pattern on whole mount pathology. Abdom Radiol (NY) 42:918-925CrossRefPubMedCentral Glazer DI, Hassanzadeh E, Fedorov A et al (2017) Diffusion-weighted endorectal MR imaging at 3T for prostate cancer: correlation with tumor cell density and percentage Gleason pattern on whole mount pathology. Abdom Radiol (NY) 42:918-925CrossRefPubMedCentral
13.
Zurück zum Zitat Shaish H, Kang SK, Rosenkrantz AB (2017) The utility of quantitative ADC values for differentiating high-risk from low-risk prostate cancer: a systematic review and meta-analysis. Abdom Radiol (NY) 42:260-270CrossRef Shaish H, Kang SK, Rosenkrantz AB (2017) The utility of quantitative ADC values for differentiating high-risk from low-risk prostate cancer: a systematic review and meta-analysis. Abdom Radiol (NY) 42:260-270CrossRef
14.
Zurück zum Zitat Renard Penna R, Cancel-Tassin G, Comperat E et al (2016) Apparent diffusion coefficient value is a strong predictor of unsuspected aggressiveness of prostate cancer before radical prostatectomy. World J Urol 34:1389-1395CrossRefPubMed Renard Penna R, Cancel-Tassin G, Comperat E et al (2016) Apparent diffusion coefficient value is a strong predictor of unsuspected aggressiveness of prostate cancer before radical prostatectomy. World J Urol 34:1389-1395CrossRefPubMed
15.
Zurück zum Zitat Renard-Penna R, Cancel-Tassin G, Comperat E et al (2015) Multiparametric Magnetic Resonance Imaging Predicts Postoperative Pathology but Misses Aggressive Prostate Cancers as Assessed by Cell Cycle Progression Score. J Urol 194:1617-1623CrossRefPubMed Renard-Penna R, Cancel-Tassin G, Comperat E et al (2015) Multiparametric Magnetic Resonance Imaging Predicts Postoperative Pathology but Misses Aggressive Prostate Cancers as Assessed by Cell Cycle Progression Score. J Urol 194:1617-1623CrossRefPubMed
16.
Zurück zum Zitat Hassanzadeh E, Glazer DI, Dunne RM, Fennessy FM, Harisinghani MG, Tempany CM (2017) Prostate imaging reporting and data system version 2 (PI-RADS v2): a pictorial review. Abdom Radiol (NY) 42:278-289CrossRef Hassanzadeh E, Glazer DI, Dunne RM, Fennessy FM, Harisinghani MG, Tempany CM (2017) Prostate imaging reporting and data system version 2 (PI-RADS v2): a pictorial review. Abdom Radiol (NY) 42:278-289CrossRef
17.
Zurück zum Zitat Warf M, Reid J, Brown K, Kimbrell H, Kolquist K (2015) Analytical Validation of a Cell Cycle Progression Signature Used as a Prognostic Marker in Prostate Cancer. J Mol Biomark Diagn 5:239 Warf M, Reid J, Brown K, Kimbrell H, Kolquist K (2015) Analytical Validation of a Cell Cycle Progression Signature Used as a Prognostic Marker in Prostate Cancer. J Mol Biomark Diagn 5:239
18.
Zurück zum Zitat Cuzick J, Swanson GP, Fisher G et al (2011) Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol 12:245-255CrossRefPubMedPubMedCentral Cuzick J, Swanson GP, Fisher G et al (2011) Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol 12:245-255CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Cuzick J, Berney DM, Fisher G et al (2012) Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br J Cancer 106:1095-1099CrossRefPubMedPubMedCentral Cuzick J, Berney DM, Fisher G et al (2012) Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br J Cancer 106:1095-1099CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Bishoff JT, Freedland SJ, Gerber L et al (2014) Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy. J Urol 192:409-414CrossRefPubMed Bishoff JT, Freedland SJ, Gerber L et al (2014) Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy. J Urol 192:409-414CrossRefPubMed
21.
Zurück zum Zitat Cooperberg MR, Simko JP, Cowan JE et al (2013) Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol 31:1428-1434CrossRefPubMed Cooperberg MR, Simko JP, Cowan JE et al (2013) Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol 31:1428-1434CrossRefPubMed
22.
Zurück zum Zitat Freedland SJ, Gerber L, Reid J et al (2013) Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy. Int J Radiat Oncol Biol Phys 86:848-853CrossRefPubMedPubMedCentral Freedland SJ, Gerber L, Reid J et al (2013) Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy. Int J Radiat Oncol Biol Phys 86:848-853CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Cuzick J, Stone S, Fisher G et al (2015) Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort. Br J Cancer 113:382-389CrossRefPubMedPubMedCentral Cuzick J, Stone S, Fisher G et al (2015) Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort. Br J Cancer 113:382-389CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Rosenkrantz AB, Ream JM, Nolan P, Rusinek H, Deng FM, Taneja SS (2015) Prostate Cancer: Utility of Whole-Lesion Apparent Diffusion Coefficient Metrics for Prediction of Biochemical Recurrence After Radical Prostatectomy. AJR Am J Roentgenol 205:1208-1214CrossRefPubMedPubMedCentral Rosenkrantz AB, Ream JM, Nolan P, Rusinek H, Deng FM, Taneja SS (2015) Prostate Cancer: Utility of Whole-Lesion Apparent Diffusion Coefficient Metrics for Prediction of Biochemical Recurrence After Radical Prostatectomy. AJR Am J Roentgenol 205:1208-1214CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Fuchsjager MH, Pucar D, Zelefsky MJ et al (2010) Predicting post-external beam radiation therapy PSA relapse of prostate cancer using pretreatment MRI. Int J Radiat Oncol Biol Phys 78:743-750CrossRefPubMedPubMedCentral Fuchsjager MH, Pucar D, Zelefsky MJ et al (2010) Predicting post-external beam radiation therapy PSA relapse of prostate cancer using pretreatment MRI. Int J Radiat Oncol Biol Phys 78:743-750CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Wei L, Wang J, Lampert E et al (2017) Intratumoral and Intertumoral Genomic Heterogeneity of Multifocal Localized Prostate Cancer Impacts Molecular Classifications and Genomic Prognosticators. Eur Urol 71:183-192CrossRefPubMed Wei L, Wang J, Lampert E et al (2017) Intratumoral and Intertumoral Genomic Heterogeneity of Multifocal Localized Prostate Cancer Impacts Molecular Classifications and Genomic Prognosticators. Eur Urol 71:183-192CrossRefPubMed
28.
Zurück zum Zitat Mohammadian Bajgiran A, Afshari Mirak S, Shakeri S et al (2018) Characteristics of missed prostate cancer lesions on 3T multiparametric-MRI in 518 patients: based on PI-RADSv2 and using whole-mount histopathology reference. Abdom Radiol (NY). https://doi.org/10.1007/s00261-018-1823-6 Mohammadian Bajgiran A, Afshari Mirak S, Shakeri S et al (2018) Characteristics of missed prostate cancer lesions on 3T multiparametric-MRI in 518 patients: based on PI-RADSv2 and using whole-mount histopathology reference. Abdom Radiol (NY). https://​doi.​org/​10.​1007/​s00261-018-1823-6
29.
Zurück zum Zitat Stocker D, Manoliu A, Becker AS et al (2018) Image Quality and Geometric Distortion of Modern Diffusion-Weighted Imaging Sequences in Magnetic Resonance Imaging of the Prostate. Invest Radiol 53:200-206CrossRefPubMed Stocker D, Manoliu A, Becker AS et al (2018) Image Quality and Geometric Distortion of Modern Diffusion-Weighted Imaging Sequences in Magnetic Resonance Imaging of the Prostate. Invest Radiol 53:200-206CrossRefPubMed
Metadaten
Titel
Extracapsular extension on MRI indicates a more aggressive cell cycle progression genotype of prostate cancer
verfasst von
Andreas G. Wibmer
Nicola L. Robertson
Hedvig Hricak
Junting Zheng
Marinela Capanu
Steven Stone
Behfar Ehdaie
Michael K. Brawer
Hebert Alberto Vargas
Publikationsdatum
27.04.2019
Verlag
Springer US
Erschienen in
Abdominal Radiology / Ausgabe 8/2019
Print ISSN: 2366-004X
Elektronische ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-019-02023-1

Weitere Artikel der Ausgabe 8/2019

Abdominal Radiology 8/2019 Zur Ausgabe

Classics in Abdominal Radiology

The “tangential calcium” sign

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.